Trial Profile
A Randomized, Double Blind, Multi-Center Study of Compound Danshen Dripping Pills in Patients With Diabetic Retinopathy (Syndrome Of Qi-Stagnation and Blood Stasis)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2019
Price :
$35
*
At a glance
- Drugs T 89 (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Sponsors Tasly Pharmaceuticals, Inc.
- 20 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.
- 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Mar 2015 New trial record